Abstract Despite a decade in, immunotherapy (IO) treatment selection in non-small cell lung cancer (NSCLC) remains largely guided by subgroup analyses and imperfect programmed death ligand 1 (PD-L1) and clinical scores. To our knowledge, I3LUNG (NCT05537922) is currently the largest international, real-world, multimodal, artificial intelligence (AI)-based study, enrolling 2,396 patients.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Vanja
Contact Vanja, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack